Drug intelligence / Profile preview

KP202

Development stage: Preclinical
Lead developer: Korea Pharma

Overview

KP202 is an early-stage investigational drug candidate being developed by Korea Pharma for the treatment of Parkinson's disease. Currently in the discovery phase, the program is part of the company's central nervous system (CNS) research pipeline. As of 2024, specific details regarding the drug's chemical structure, modality, and precise mechanism of action remain proprietary and have not been disclosed in public clinical or scientific literature. The asset is listed on the sponsor's Korean-language pipeline but is notably absent from the English-language version of their corporate website.

Beyond the preview

Go deeper on KP202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KP202.

Explore the full profile